<DOC>
	<DOCNO>NCT01357603</DOCNO>
	<brief_summary>The aim trial demonstrate bioequivalence Glaritus® Lantus® regard total maximum serum insulin concentration .</brief_summary>
	<brief_title>Comparative Glucose Clamp Study Wockhardt 's Recombinant Insulin Analog Glargine ( Glaritus ) With Lantus T1DM</brief_title>
	<detailed_description>The purpose study test bioequivalence base pharmacokinetic parameter AUC INS-GLR 0-24h pharmacodynamic parameter AUC GIR 0-24h two long-acting insulin glargine formulation , Lantus® Wockhardt 's Glaritus® subject type1 diabetes well assess safety local tolerability two insulin preparation .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Male female subject type 1 diabetes ≥12 month . 2 . HbA1c ≤9 % local laboratory analysis ( one retest within week permit result last test conclusive ) . 3 . Age ≥18 ≤60 year . 4 . Considered generally healthy upon completion medical history , physical examination biochemical investigation judge Investigator . 5 . Signed date informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) . 1 . Previous participation trial , participation clinical trial within last 30 day . 2 . Pregnant , breastfeed intention become pregnant use adequate contraceptive measure ( e.g . intrauterine device ( IUD ) place least 3 month , sterilization , oral contraceptive pill , take without difficulty least 3 month , approve hormonal implant double barrier method include male condom use plus spermicide , diaphragm spermicide plus male condom , cap spermicide plus male condom ) . 3 . History illness , opinion Investigator , might confound result trial pose risk administer trial drug subject . In particular , subject significant cardiovascular disease , anemia ( hemoglobin low limit normal ) hemoglobinopathy allow enter trial . 4 . Cardiac problem define decompensated heart failure ( New York Heart Association ( NYHA ) class III IV ) time and/or angina pectoris within last 12 month and/or acute myocardial infarction time . 5 . Clinically significant abnormal ECG screening , judge Investigator . 6 . History alcohol drug abuse past five year . 7 . Any positive reaction drug abuse . 8 . Hepatitis B C HIV positive . 9 . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation . 10 . History multiple and/or severe allergy drug food history severe anaphylactic reaction . 11 . Regular cigarette smoker , define smoke &gt; 1 pack/day unable refrain smoking house period . 12 . Known suspect allergy trial product relate product . 13 . Any disease condition , opinion Investigator , would represent unacceptable risk subject 's safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>